Case Submission

Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 6.25 Contact Hours.

Acknowledgment of Commercial Support

This educational activity is supported by educational grants from Amgen, Inc.; AstraZeneca; Bristol Myers Squibb; and Pfizer Inc.

5th Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application

5th Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application

Virtual Interactive Conference!

Saturday, December 12, 2020 - 8:00 AM – 3:10 PM EST


The diagnosis, risk stratification, and treatment of cancer have become increasingly personalized based on novel testing technologies and targeted agents that clinicians can apply based on predictive biomarkers. The advent of newer and less invasive approaches to diagnosis such as liquid biopsy is enabling clinicians to diagnose a wider variety of cancers at earlier stages. Novel immunotherapy agents used alone or in combination with other agents may further optimize outcomes for patients with advanced tumors. Clinicians require a practical working knowledge of biomarkers, immune pathways, and the mechanisms of action of immunotherapeutic strategies to effectively tailor optimal treatment for their patients.

The 5th Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application is specifically designed to aid clinicians in assessing the emerging data in cancer immunotherapy, including immune checkpoint blockade, metabolic blockade, vaccines, chimeric antigen receptor T-cell therapy, oncolytic viruses, and agonist costimulatory antibodies. The meeting will be divided into multiple sections—each focusing on different tumors and hematologic malignancies, including lung cancers, melanoma, genitourinary cancers, and hematology—and include a mix of brief presentations on new data, panel discussions, and case reviews that guide the implementation of core concepts into the clinic.

Acknowledgment of Commercial Support

This educational activity is supported by educational grants from Amgen, Inc.; AstraZeneca; Bristol Myers Squibb; and Pfizer Inc.

Benefits of Attending

  • Gain a better understanding of how the immune system is targeted to treat cancer
  • Improve your confidence in applying immunotherapeutic strategies to treat patients with cancer
  • Improve your use of molecular testing to guide treatments for patients with cancer
  • Become better prepared to monitor and manage treatment-related toxicities for patients who receive immunotherapy

Target Audience

This educational activity is directed toward medical oncologists, nurse practitioners, and pharmacists who treat patients with cancer. Participants are primarily those whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on immunotherapies and their evolving roles in the treatment of patients with cancer. Nurses, physician assistants, fellows, investigators, and other health care professionals interested in the treatment of cancer are invited to participate.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Explore the mechanisms of action for immunotherapeutic strategies and their application to cancer management
  • Outline clinical trial evidence on immunotherapy and the unmet clinical needs that these trials are designed to address
  • Apply key trial data to the management of solid and hematologic malignancies in multiple lines of care
  • Integrate evolving testing approaches to stratify risk and facilitate the identification of biomarkers related to the application of immunotherapeutic approaches
  • Implement practical strategies to monitor for and manage treatment-related toxicities among patients who receive single-agent and combination immunotherapeutic approaches to manage their cancer

Hot Topics

  • New and Emerging Tumor Biomarkers
  • Advances in Immunotherapies for Solid Tumors and Hematologic Malignancies
  • Managing the Treatment-Related Toxicities of Immunotherapy

Program Co-Chairs

Naiyer Rizvi
Naiyer Rizvi, MD
Professor of Medicine
Director, Thoracic Oncology
Co-Director, Cancer Immunotherapy Programs
Price Chair, Clinical Translational Research
Columbia University
Irving Medical Center
New York, NY
Mario Sznol
Mario Sznol, MD
Professor of Medicine (Medical Oncology)
Yale School of Medicine
Program Leader, Melanoma
Co-Leader, Cancer Immunology Program
Yale Cancer Center
New Haven, CT


2 Ways to Register
  1. Online: Click here.
  2. Phone: Please call (888) 949-0045 or (609) 378-3701 (credit cards only).

Physicians' Education Resource®, LLC - ICIC19
2 Clarke Drive
Suite 110
Cranbury, NJ 08512

Registration Fees

Physicians $75
Fellows* $50
Nurses, PAs, Other Health Care Professionals $50
Industry** $199

*FELLOWS registration must be accompanied by a letter from your director/chair stating current fellowship for discount.

**INDUSTRY is defined by PER® as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical.

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

A cancellation fee of 25% will be assessed on refunds requested through and including October 31, 2020, and a 50% fee on refunds requested on November 1, 2020 through November 28, 2020. No refunds will be made after November 30, 2019. There is no charge for substitution. Substitutions can only be applied to the same conference and only two substitutions will be honored.

In the event of a meeting cancellation, full refunds will be processed within 30 days of the cancellation date.

PER® reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited. This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting continuing education materials.

Meeting information is accurate at the time of posting.


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

Professional Information


Calendar of Events
Filter By